title icon

Patents and Intellectual Property

We control a portfolio of technologies which may be applied to cancer and other diseases. The Company holds worldwide exclusive licenses to 30 issued and 6 pending patents for technologies developed by researchers at the National Cancer Institute, The University of Texas MD Anderson Cancer Center, and The University of Texas Southwestern Medical Center. The issued and pending patents include the U.S., Europe, Japan, Australia, and other commercially important regions. These patents comprise various therapeutic, diagnostic, technical and processing claims.